Written question asked by Lord Hunt of Kings Heath (Labour) on Wednesday, 25 March 2026, in the House of Lords. It was due for an answer on Friday, 10 April 2026. It was answered by Baroness Merron (Labour) on Thursday, 16 April 2026 on behalf of the Department of Health and Social Care.

Liothyronine

Question: To ask His Majesty's Government, given that NHS England’s 2023 guidance Liothyronine – advice for prescribers sets out a complete national prescribing pathway without including any requirement for local prior approval processes, what steps are they taking to ensure that Integrated Care Boards act consistently with this guidance.

Answer

NHS England’s policy guidance and prescribing advice on liothyronine reflects the National Institute for Health and Care Excellence’s recommendations and the evidence on liothyronine. That guidance recommends that liothyronine should not be routinely prescribed, because it is not clinically or cost-effective, but sets out the exceptions where it may be an appropriate consideration for prescribers.

NHS England expects commissioners and prescribers to have due regard to its guidance. While integrated care boards may determine their own implementation arrangements, as part of the new operating model, regions will oversee commissioner and provider performance, including access to high quality care and the reduction of health inequalities.

Secondary information

Type: Written question
Reference: HL15992
Session: 2024-26
Grouped for answer: Yes
Subjects: Liothyronine
Link: View this Written question on www.parliament.uk

Liothyronine

Secondary information

Librarians' tools